Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common stock, $0.001 par value per share
-
Number of holders
-
45
-
Total 13F shares, excl. options
-
14.7M
-
Shares change
-
+6.51M
-
Total reported value, excl. options
-
$28.7M
-
Value change
-
+$12.7M
-
Put/Call ratio
-
4.82
-
Number of buys
-
26
-
Number of sells
-
-14
-
Price
-
$1.96
Significant Holders of LEAP THERAPEUTICS, INC. - Common stock, $0.001 par value per share (LPTX) as of Q2 2024
54 filings reported holding LPTX - LEAP THERAPEUTICS, INC. - Common stock, $0.001 par value per share as of Q2 2024.
LEAP THERAPEUTICS, INC. - Common stock, $0.001 par value per share (LPTX) has 45 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 14.7M shares
.
Largest 10 shareholders include Balyasny Asset Management L.P. (3.1M shares), Samsara BioCapital, LLC (2.44M shares), 683 Capital Management, LLC (1.3M shares), Rock Springs Capital Management LP (1.27M shares), BAKER BROS. ADVISORS LP (1.17M shares), VANGUARD GROUP INC (996K shares), CITADEL ADVISORS LLC (918K shares), Laurion Capital Management LP (709K shares), Simplify Asset Management Inc. (631K shares), and Key Client Fiduciary Advisors, LLC (285K shares).
This table shows the top 45 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.